Back to top
more

G1 THERAPEUTICS (GTHX)

(Delayed Data from NSDQ)

$21.61 USD

21.61
229,042

+0.72 (3.45%)

Updated May 3, 2019 04:00 PM ET

After-Market: $21.60 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Brokerage Reports

[GTHX]

Reports for Purchase

Showing records 161 - 180 ( 361 total )

Industry: Medical - Biomedical and Genetics

Record: 161

06/10/2021

Industry Report

Pages: 23

ASCO 2021: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 162

06/07/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 163

06/07/2021

Company Report

Pages: 7

Updated Data for Rintodestrant in Combination With Ibrance for ER+/HER2- Advanced Breast Cancer at ASCO 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 164

06/05/2021

Company Report

Pages: 10

Update on Rintodestrant and Trilaciclib Presented at ASCO 2021

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 165

05/20/2021

Industry Report

Pages: 10

ASCO 2021 Abstracts Released

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 166

05/20/2021

Company Report

Pages: 5

Positive Rintodestrant Combination Data in ASCO Abstract

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 167

05/10/2021

Daily Note

Pages: 3

Phase 2 PRESERVE 4 Study of Cosela in NSCLC Patients Previously Treated with Checkpoint Inhibitors Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 168

05/06/2021

Daily Note

Pages: 15

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 169

05/06/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 170

05/06/2021

Company Report

Pages: 7

COSELA Catching On

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 171

05/06/2021

Company Report

Pages: 6

1Q21: Key Word--EXECUTE On the COSELA Launch and New Clinical Trials

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 172

05/06/2021

Company Report

Pages: 6

1Q21 Results; Cosela Launch Progressing Nicely; Five Potential Label Expansion Studies Could be Underway by Year End

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 173

04/28/2021

Daily Note

Pages: 3

Pivotal Phase 3 Trial of Cosela in TNBC Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 174

04/12/2021

Company Report

Pages: 8

G1 Therapeutics Virtual Analyst and Investor Summit Focuses on Cosela Launch and Potential for SCLC Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 175

04/09/2021

Daily Note

Pages: 5

COSELA Kick Off: Spare the Marrow, Spear the Tumor

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 176

04/09/2021

Company Report

Pages: 6

G1 Discusses COSELA Campaign: Spare the Marrow, Spear the Tumor

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 177

04/09/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 178

03/29/2021

Industry Report

Pages: 19

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 179

03/26/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 180

03/25/2021

Company Report

Pages: 5

Cosela Included in NCCN Oncology Guidelines. Raising Revenue.

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party